Synchroneuron

About Synchroneuron

Synchroneuron, Inc. operates as a clinical-stage biopharmaceutical company focused on creating treatments for neuropsychiatric disorders. Established in 2011, the firm was co-founded by neurologist Dr. Barry Fogel, along with William Kerns, Marc Cote, and Kei-Lai Fong. The concept for the company's core therapy was pioneered by Dr. Fogel, a neuropsychiatrist and behavioral neurologist at Brigham and Women's Hospital and a Clinical Professor of Psychiatry at Harvard Medical School.

The company is developing novel therapies for conditions such as tardive dyskinesia (TD), a movement disorder caused by prolonged exposure to certain medications. Synchroneuron's business model centers on the development and eventual commercialization of its proprietary drug candidates. The company has successfully raised capital through venture funding to advance its clinical programs. Significant financial milestones include a $6 million Series A round in 2012 and a $20 million Series B round in 2014, both led by Morningside Technology Ventures.

Synchroneuron's lead product candidate is SNC-102, a sustained-release formulation of acamprosate calcium. Acamprosate calcium is already an FDA-approved drug for treating alcohol dependence. Synchroneuron developed SNC-102 to have improved pharmacokinetic properties, allowing for sustained plasma levels of the active compound. The drug aims to modulate both excitatory and inhibitory neurotransmission pathways, specifically targeting glutamate/GABA imbalance. Beyond tardive dyskinesia, the company has explored the potential of SNC-102 in treating other neuropsychiatric conditions, including Tourette syndrome and post-traumatic stress disorder (PTSD). Phase 1 studies showed promising results, and the company has advanced SNC-102 into Phase 2 clinical trials.